Group 1: TransMedics Group - TransMedics Group has developed an innovative Organ Care System (OCS) that significantly improves organ storage before transplants, achieving an 81% usage rate for hearts compared to 32% for traditional cold storage [4] - The company has faced challenges, including slowed revenue growth and disappointing guidance, alongside serious allegations from an activist short-seller [5] - Despite recent issues, TransMedics Group's stock rose approximately 20% following stronger-than-expected first-quarter results, although shares are still down 11% over the past year, indicating potential for significant upside in the next five years [6][7] Group 2: Exact Sciences - Exact Sciences specializes in cancer diagnostic tests, notably Cologuard, a non-invasive test for colorectal cancer, which is the second leading cause of cancer death globally [8] - The company has made substantial progress in the screening market, with Cologuard being used to screen 10 million patients by 2022 since its U.S. clearance in 2014 [9] - Recent advancements include the approval of Cologuard Plus, which is more effective and cheaper to manufacture, and the launch of Oncodetect for cancer recurrence checks, with plans for a multicancer-detecting test called Cancerguard later this year [10][11][12]
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years